For me and like others have said, it appears to be an extremely...

For me and like others have said, it appears to be an extremely positive announcement on the way, and like others have said, do don't present at these large conferences if you have disappointing results. Interesting how the investor presentation wasn't flagged with a "Market Sensitive" notice, does anyone know if the company flags their releases as market-sensitive or does the ASX determine it?

Love these sections of the presentation the most:

"Results of the first phase to be co-presented with
Janssen at the world's leading diabetes conference,
the 80th Scientific Sessions of the American Diabetes
Association (ADA) on 13th June 2020"

"If successful, it will be independent, Big Pharma
validation of PromarkerD - this will be significant for
the commercialisation and promotion of PromarkerD
in the US and globally"

"Potential for PromarkerD to become a Complementary
Diagnostic (CDx) means a PromarkerD test could be
used:
▪ upon prescription of drug treatments for diabetes
▪ throughout a patient’s course of treatment
(potentially lifetime) to monitor the ongoing risk of
developing chronic kidney disease"

"Invokana™ revenue fell to US$881 million in 2018
from US$1.4 billion in 2016* - opportunity for
Janssen to turn this around with PromarkerD"

"Upcoming FDA regulatory approval process should be
accelerated by using the Janssen/PromarkerD data"